دورية أكاديمية
أعرض في EDS

Population-Based Analysis of the Immunoglobulin G Response to Different COVID-19 Vaccines in Brazil.

التفاصيل البيبلوغرافية
العنوان: Population-Based Analysis of the Immunoglobulin G Response to Different COVID-19 Vaccines in Brazil.
المؤلفون: Paula NM; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil.; Graduated Program in Sciences-Biochemistry, UFPR, Curitiba 81531-980, PR, Brazil., Conzentino MS; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil.; Graduated Program in Sciences-Biochemistry, UFPR, Curitiba 81531-980, PR, Brazil., Gonçalves ACA; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil., da Silva R; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil.; Graduated Program in Sciences-Biochemistry, UFPR, Curitiba 81531-980, PR, Brazil., Weissheimer KV; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil., Kluge CHS; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil., Marins PHSA; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil., Camargo HSC; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil., Farias LRP; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil., Sant'Ana TP; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil., Vargas LR; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil., Aldrighi JD; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil., Lima ÊS; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil., Jacotenski GT; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil., Pedrosa FO; Graduated Program in Sciences-Biochemistry, UFPR, Curitiba 81531-980, PR, Brazil., Gonçalves AG; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil.; Graduated Program in Farmacy, UFPR, Curitiba 80060-240, PR, Brazil., Joucoski E; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil., Huergo LF; Setor Litoral, Federal University of Paraná, UFPR, Matinhos 83260-000, PR, Brazil.; Graduated Program in Sciences-Biochemistry, UFPR, Curitiba 81531-980, PR, Brazil.
المصدر: Vaccines [Vaccines (Basel)] 2022 Dec 22; Vol. 11 (1). Date of Electronic Publication: 2022 Dec 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG
مستخلص: (1) Background: COVID-19 vaccination in Brazil has been performed mostly with CoronaVac (Sinovac), ChAdOx1-S (AstraZeneca-University of Oxford) and BNT162b2 (Pfizer-BioNTech) vaccines. The titers of IgG antibodies reactive to the SARS-CoV-2 spike protein correlate with vaccine efficacy. Studies comparing vaccine immunogenicity in a real-world scenario are lacking. (2) Methods: We performed a population-based study to analyze the immunoglobulin G response to different COVID-19 vaccines. Citizens older than 18 years (n = 2376) provided personal data, a self-declaration of any previous COVID-19 positive tests and information regarding COVID-19 vaccination: the vaccine popular name and the date of each dose. Blood samples were collected and the levels of IgG reactive to SARS-CoV-2 antigens were determined and compared between different vaccine groups. (3) Results: The seroconversion for anti-spike IgG achieved > 95% by February 2022 and maintained stable until June 2022. Higher anti-spike IgG titers were detected in individuals vaccinated with BNT162b2, followed by ChAdOx1-S and CoronaVac. The anti-spike IgG response was negatively correlated with age and interval after the second dose for the BNT162b2 vaccine. Natural infections boosted anti-spike IgG in those individuals who completed primary vaccination with ChAdOx1-S and CoronaVac, but not with BNT162b2. The levels of anti-spike IgG increased with the number of vaccine doses administered. The application of BNT162b2 as a 3rd booster dose resulted in high anti-spike IgG antibody titers, despite the type of vaccine used during primary vaccination. (4) Conclusions: Our data confirmed the effectiveness of the Brazilian vaccination program. Of the vaccines used in Brazil, BNT162b2 performed better to elicit anti-spike protein IgG after primary vaccination and as a booster dose and thus should be recommended as a booster whenever available. A continuous COVID-19 vaccination program will be required to sustain anti-spike IgG antibodies in the population.
References: Nat Med. 2022 Apr;28(4):838-843. (PMID: 35140406)
Nat Commun. 2021 Aug 6;12(1):4740. (PMID: 34362897)
Lancet. 2021 Jul 17;398(10296):213-222. (PMID: 34246358)
ACS Sens. 2021 Mar 26;6(3):703-708. (PMID: 33496577)
Microbiol Spectr. 2022 Aug 31;10(4):e0102622. (PMID: 35770982)
Anal Biochem. 2021 Oct 15;631:114360. (PMID: 34481802)
Science. 2022 Jan 07;375(6576):43-50. (PMID: 34812653)
Nat Med. 2021 Oct;27(10):1744-1751. (PMID: 34331051)
Braz J Microbiol. 2021 Dec;52(4):2069-2073. (PMID: 34342836)
Nat Rev Immunol. 2021 Aug;21(8):475-484. (PMID: 34211186)
Lancet Microbe. 2022 Apr;3(4):e274-e283. (PMID: 35165669)
Braz J Microbiol. 2022 Sep;53(3):1263-1269. (PMID: 35426068)
Viruses. 2022 Apr 14;14(4):. (PMID: 35458539)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
Nat Med. 2021 Nov;27(11):2032-2040. (PMID: 34588689)
Lancet. 2022 Feb 5;399(10324):521-529. (PMID: 35074136)
Lancet. 2021 Jan 9;397(10269):99-111. (PMID: 33306989)
N Engl J Med. 2021 Jun 10;384(23):2187-2201. (PMID: 33882225)
Nature. 2022 Feb;602(7898):671-675. (PMID: 35016199)
Nature. 2022 Feb;602(7898):682-688. (PMID: 35016197)
Biochem Eng J. 2022 Aug;186:108537. (PMID: 35874089)
Nat Rev Microbiol. 2021 Mar;19(3):141-154. (PMID: 33024307)
Front Immunol. 2022 Jun 09;13:918896. (PMID: 35757764)
Front Immunol. 2022 Feb 28;13:809285. (PMID: 35296086)
Nature. 2022 Mar;603(7902):715-720. (PMID: 35104836)
فهرسة مساهمة: Keywords: SARS-CoV-2; humoral response; vaccine
تواريخ الأحداث: Date Created: 20230121 Latest Revision: 20230308
رمز التحديث: 20230308
مُعرف محوري في PubMed: PMC9862407
DOI: 10.3390/vaccines11010021
PMID: 36679871
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-393X
DOI:10.3390/vaccines11010021